EMERYVILLE, Calif.—NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company developing products for the eyecare market, has announced financial results for the three and six months ended June 30, 2024. Total revenue for the second quarter of 2024 was $2.4 million compared with $3.5 million in the second quarter last year. Net sales for the second quarter of 2024 were derived predominantly from sale of eyecare products, the company said, which increased 8 percent over the prior year due to more Avenova-branded products sold through online channels. Read More